MyJournals Home  

RSS FeedsChromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One (European Urology Oncology)

 
 

20 march 2020 02:03:10

 
Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One (European Urology Oncology)
 


We read with interest a recent paper published in European Urology Oncology by Graham et al [1]. The paper describes `treatment sequence and assess clinical effectiveness of targeted therapy for metastatic renal cell carcinoma (mRCC) patients who received prior immuno-oncology therapy` [1]. Our interest focused on a small set of their patients included in the study--those with chromophobe mRCC, that is, five out of 314 (1.6%) patients (pathology data were available for 298; no further data on those tumors, such as grading or presence of sarcomatoid differentiation, were included).


 
25 viewsCategory: Oncology, Urology
 
Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review (European Urology Oncology)
Primum Non Nocere: When Nephrectomy Becomes a Selective Approach in Metastatic Renal Cell Carcinoma (European Urology Oncology)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:


Copyright © 2008 - 2020 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten